X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (529) 529
Publication (30) 30
Book Chapter (6) 6
Book Review (6) 6
Conference Proceeding (2) 2
Book / eBook (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (320) 320
oncology (300) 300
female (191) 191
male (169) 169
middle aged (169) 169
united states (160) 160
index medicus (159) 159
aged (154) 154
united states food and drug administration (146) 146
drug approval (143) 143
adult (135) 135
antineoplastic agents - therapeutic use (97) 97
treatment outcome (79) 79
cancer (77) 77
chemotherapy (63) 63
aged, 80 and over (60) 60
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
clinical trials as topic (47) 47
disease-free survival (46) 46
fda (45) 45
randomized controlled trials as topic (39) 39
colorectal neoplasms - drug therapy (38) 38
neoplasms - drug therapy (37) 37
regulatory issues (37) 37
antineoplastic agents - adverse effects (36) 36
survival (36) 36
neoplasm metastasis (35) 35
fluorouracil - administration & dosage (33) 33
pharmacology & pharmacy (33) 33
regulatory issues: fda (33) 33
trial (32) 32
drug administration schedule (31) 31
lung neoplasms - drug therapy (31) 31
clinical trials (30) 30
adenocarcinoma - drug therapy (29) 29
fda approval (29) 29
5-fluorouracil (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (28) 28
survival analysis (28) 28
carcinoma, non-small-cell lung - drug therapy (27) 27
fluorouracil (27) 27
infusions, intravenous (27) 27
therapy (27) 27
breast neoplasms - drug therapy (26) 26
neoplasm staging (25) 25
patients (24) 24
animals (23) 23
adolescent (22) 22
carcinoma (22) 22
disease progression (22) 22
drug evaluation (22) 22
immunotherapy (22) 22
antibodies, monoclonal - adverse effects (21) 21
docetaxel (21) 21
time factors (21) 21
administration, oral (20) 20
antineoplastic agents - administration & dosage (20) 20
abridged index medicus (19) 19
antineoplastic agents - pharmacology (18) 18
confidence intervals (18) 18
drug therapy (18) 18
fluorouracil - therapeutic use (18) 18
metastasis (18) 18
regulatory agencies (18) 18
antibodies, monoclonal - administration & dosage (17) 17
chemotherapy, adjuvant (17) 17
colorectal cancer (17) 17
leucovorin - administration & dosage (17) 17
metastases (17) 17
multiple myeloma - drug therapy (17) 17
protein kinase inhibitors - therapeutic use (17) 17
uracil - administration & dosage (17) 17
antineoplastic agents (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
colorectal neoplasms - pathology (16) 16
dose-response relationship, drug (16) 16
drug approval - legislation & jurisprudence (16) 16
piperazines - therapeutic use (16) 16
carcinoma, non-small-cell lung - pathology (15) 15
care and treatment (15) 15
double-blind method (15) 15
phase-ii (15) 15
phase-iii trial (15) 15
antimetabolites, antineoplastic - therapeutic use (14) 14
clinical trials, phase ii as topic (14) 14
combined modality therapy (14) 14
fluorouracil - adverse effects (14) 14
follow-up studies (14) 14
imatinib mesylate (14) 14
irinotecan (14) 14
pyrimidines - therapeutic use (14) 14
tegafur - administration & dosage (14) 14
antibodies, monoclonal - therapeutic use (13) 13
camptothecin - analogs & derivatives (13) 13
deoxycytidine - analogs & derivatives (13) 13
leucovorin (13) 13
leukemia (13) 13
lung neoplasms - pathology (13) 13
multicenter studies as topic (13) 13
pyridines - adverse effects (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Investigative Medicine, ISSN 1708-8267, 2004, Volume 52, Issue 4, pp. 217 - 219
Journal Article
The Oncologist, ISSN 1083-7159, 04/2008, Volume 13, Issue 2, pp. 19 - 21
Overall survival remains the gold standard for the demonstration of clinical benefit. An improvement in overall survival is a direct clinical benefit to... 
Endpoints | Time to progression | Response rate | Survival | APPROVAL | endpoints | time to progression | ONCOLOGY | survival | response rate | Humans | Endpoint Determination | Survival Analysis | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Disease Progression | Neoplasms - drug therapy
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2438 - 2441
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2004, Volume 22, Issue 22, pp. 4626 - 4631
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 03/2019, Volume 16, Issue 3, pp. 139 - 141
In 2018, the FDA approved 19 new drug and biologic applications, 38 supplemental drug and biologic applications and 4 biosimilar applications in oncology.... 
ONCOLOGY | Antimitotic agents | Care and treatment | Squamous cell carcinoma | Leukemia | Lymphomas | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents | Prostate cancer | Drug approval | Minimal residual disease | Histology | Metastases
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1504 - 1505
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 2018, Volume 17, Issue 8, pp. 529 - 530
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 03/2018, Volume 15, Issue 3, pp. 127 - 128
In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in... 
ONCOLOGY | Product development | Gene therapy | Pharmaceutical industry | Licensing, certification and accreditation
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 26, pp. 2458 - 2460
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2018, Volume 24, Issue 8, pp. 1780 - 1784
Cancer therapeutics frequently lead to symptomatic adverse events (AE) that can affect treatment tolerability. The NCI has developed the Patient-Reported... 
PATIENT | OUTCOMES | ONCOLOGY | ADVERSE EVENTS | Clinical trials | Medical research | Safety | Patients | Cancer | Quality of life
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.